Dasatinib
- PDF / 169,714 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 62 Downloads / 130 Views
1 S
Chylothorax: case report An 80-year-old woman developed chylothorax during treatment with dasatinib for chronic myeloid leukaemia (CML). The woman presented to the hospital with a 2 week history of worsening non-productive cough and shortness of breath. She was a non-smoker. Her medical history was notable for CML, which was diagnosed in 2007, hypertension, hypothyroidism, metallic aortic valve replacement, chronic kidney disease, congestive cardiac failure, gout and hypercholesterolaemia. Her previous treatment included imatinib; however this was changed to dasatinib [route and dosage not stated] in 2009 because of gastric ectasia. Chest x-ray with subsequent CT thorax showed a large right sided pleural effusion. The woman underwent thoracocentesis, and milky fluid was sent for evaluation. Despite drainage, she developed a recurrence of the chylothorax. She underwent lymphoscintogram without any evidence of a thoracic duct leak. In the absence of an alternative cause, a diagnosis of dasatinib associated chylothorax was considered [duration of treatment to reaction onset not stated], and dasatinib was discontinued. She was put on a reduced lipid diet with increase in diuretic. A short course of prednisolone was also added. Eventually, she underwent a successful pleurodesis. O’Brien S, et al. A case of a chylous complication related to Dasatinib use. American Journal of Respiratory and Critical Care Medicine 199: (plus poster) abstr. A1490, No. 803446541 9, May 2019. Available from: URL: http://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1490 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
